These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25216371)

  • 1. Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.
    Sampaio C; Borowsky B; Reilmann R
    Mov Disord; 2014 Sep; 29(11):1419-28. PubMed ID: 25216371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Huntington's disease: advances in care and emerging therapeutic options.
    Zielonka D; Mielcarek M; Landwehrmeyer GB
    Parkinsonism Relat Disord; 2015 Mar; 21(3):169-78. PubMed ID: 25572500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor outcome measures in Huntington disease clinical trials.
    Reilmann R; Schubert R
    Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep brain stimulation in Huntington's disease: assessment of potential targets.
    Sharma M; Deogaonkar M
    J Clin Neurosci; 2015 May; 22(5):812-7. PubMed ID: 25698541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report.
    Hebb MO; Garcia R; Gaudet P; Mendez IM
    Neurosurgery; 2006 Feb; 58(2):E383; discussion E383. PubMed ID: 16462466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive interventions to enhance neural compensation in Huntington's disease.
    Andrews SC; Domínguez JF; Mercieca EC; Georgiou-Karistianis N; Stout JC
    Neurodegener Dis Manag; 2015; 5(2):155-64. PubMed ID: 25894879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's Disease Clinical Trials Corner: June 2019.
    Rodrigues FB; Ferreira JJ; Wild EJ
    J Huntingtons Dis; 2019; 8(3):363-371. PubMed ID: 31381524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.
    Bohanna I; Georgiou-Karistianis N; Hannan AJ; Egan GF
    Brain Res Rev; 2008 Jun; 58(1):209-25. PubMed ID: 18486229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain stimulation in Huntington's disease.
    Hartmann CJ; Groiss SJ; Vesper J; Schnitzler A; Wojtecki L
    Neurodegener Dis Manag; 2016 Jun; 6(3):223-36. PubMed ID: 27230813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.
    Aylward EH
    Mov Disord; 2014 Sep; 29(11):1429-33. PubMed ID: 25164586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward.
    Bachoud-Lévi AC; Massart R; Rosser A
    Stem Cells; 2021 Feb; 39(2):144-155. PubMed ID: 33176057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Huntington's disease: clinical and molecular genetics].
    Warita H; Shiro Y; Kashihara K; Abe K
    Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials Corner: September 2017.
    Rodrigues FB; Wild EJ
    J Huntingtons Dis; 2017; 6(3):255-263. PubMed ID: 28968245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and outcome of pallidal deep brain stimulation in severe Huntington's disease.
    Huys D; Bartsch C; Poppe P; Lenartz D; Huff W; Prütting J; Timmermann L; Klosterkötter J; Maarouf M; Rommel T; Hartmann A; Sturm V; Kuhn J
    Fortschr Neurol Psychiatr; 2013 Apr; 81(4):202-5. PubMed ID: 23589113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.